We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

27 hedge funds and large institutions have $12.6M invested in Regulus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

37.41% more ownership

Funds ownership: 4.16% → 41.57% (+37%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

25% less funds holding

Funds holding: 36 → 27 (-9)

31% less capital invested

Capital invested by funds: $18.1M → $12.6M (-$5.52M)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

Holders
27
Holders Change
-9
Holders Change %
-25%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
10
Closed
16
Calls
$1.28M
Puts
–
Net Calls
+$1.28M
Net Calls Change
+$1.09M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$58.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$57.4K
3
BlackRock
BlackRock
New York
+$51.4K
4
Renaissance Technologies
Renaissance Technologies
New York
+$35.8K
5
VF
Virtu Financial
New York
+$24.8K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$57.2K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$55K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$51K
4
Two Sigma Investments
Two Sigma Investments
New York
-$34K
5
GC
Grimes & Company
Massachusetts
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
– -$55K -18,460 Closed
Two Sigma Advisers
27
Two Sigma Advisers
New York
– -$51K -17,050 Closed
Two Sigma Investments
28
Two Sigma Investments
New York
– -$34K -11,444 Closed
GC
29
Grimes & Company
Massachusetts
– -$26K -8,820 Closed
Jane Street
30
Jane Street
New York
– -$22K -7,364 Closed
WA
31
WealthTrust Axiom
Pennsylvania
– -$20K -6,800 Closed
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
– -$16K -6,583 Closed
Lido Advisors
33
Lido Advisors
California
– -$16K -5,450 Closed
Millennium Management
34
Millennium Management
New York
– -$15K -4,889 Closed
GFS
35
GYL Financial Synergies
Connecticut
– -$10K -3,400 Closed
ATFA
36
All Terrain Financial Advisors
Minnesota
– -$4K -1,500 Closed
MIG
37
McGuire Investment Group
Rhode Island
– -$4K -1,500 Closed
Creative Planning
38
Creative Planning
Kansas
– -$4K -1,200 Closed
DY
39
Dowling & Yahnke
California
– -$4K -1,200 Closed
William Blair & Company
40
William Blair & Company
Illinois
– -$3K -1,120 Closed
EWM
41
Endurance Wealth Management
Rhode Island
– -$2K -675 Closed
Rockefeller Capital Management
42
Rockefeller Capital Management
New York
– +$2 +1 New
Citigroup
43
Citigroup
New York
– +$19 +8 New
1
2

RGLS Hedge Fund Activity: Q2 2022 in Review

27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2022, worth a combined $12.6M — down 31% from $18.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RGLS and 7 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was State Street, adding an estimated $58.4K. The largest seller was Ikarian Capital, cutting an estimated $57.2K.

  • 27 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2022, down from 36 in Q1 2022.
  • Funds reported $12.6M of Regulus Therapeutics stock for Q2 2022, down 31% quarter-over-quarter.
  • 7 funds opened new Regulus Therapeutics positions in Q2 2022 and 16 closed out, a net change of -9 holders.
  • The largest Regulus Therapeutics buyer in Q2 2022 was State Street, an estimated $58.4K added.
  • The largest Regulus Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $57.2K sold.

Based on aggregated 13F filings for Q2 2022.